February 12, 2019
With the Japanese green light for Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) looming, the health ministry will report its plans to approve a series of pre-treatment conditioning regimens for the product at a key panel meeting on February 22...read more